None listed
Conditions
Interventions
Intervention1: Treatment B: Amitriptyline Hydrochloride, 25 mg: Dose
Frequency of administration: single oral dose
route of administration: Oral
Intervention2: Treatment C: Amitriptyline Hydrochloride, 25 mg: Dose
Frequency of administration: single oral dose
route of administration: Oral
Control Intervention1: Treatment A : Amitriptyline Hydrochloride, 25 mg: Dose
Frequency of administration: single oral dose
Sponsors
Sun Pharma Advanced Research Company Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Healthy, adult males and females aged 18 to 45 years, inclusive, at screening 2. Body mass index (BMI) greater than equal to 18 to less than equal to 32 kg/m2 and total body weight greater than 50 kg (110 lbs) at screening. 3. Subject is able and willing to provide written informed consent and to complete all study procedures 4. Females of childbearing potential must not be pregnant (as confirmed by a negative serum pregnancy test) or lactating. 5. Women of childbearing potential must agree to use contraception (barrier method) throughout the study. 6. Male subjects must agree to use an acceptable form of birth control to prevent pregnancy in the female partner and must agree not to donate the sperm throughout the duration of the study. 7. Medically healthy on the basis of medical history and physical examination (including but not limited to an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems), as determined by the Investigator. 8. Subjects not having clinically significant history or signs of significant hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease, or active sexually transmitted disease. 9. Medically healthy based on the absence of clinically significant abnormal vital sign measurements, clinical laboratory test results (especially tests for renal and hepatic function) or ECG parameters (including sick sinus syndrome, second- or third- degree atrial ventricular block, cardiogenic shock and decompensated heart failure), as determined by the Investigator. 10. The subject must be willing and able to comply with study restrictions and able to remain at the clinic for the required duration during the study, and is willing to return to the clinic for the follow-up evaluation as specified in this protocol.
Exclusion criteria
Exclusion criteria: 1. History of allergic reaction or a severe adverse reaction to amitriptyline or any other antidepressants or related excipients 2. History of alcohol or substance abuse within the past 12 months (DSM-V definition of alcohol or substance abuse) 3. History of depression, seizure (including febrile seizure), syncope or loss of consciousness due to head trauma 4. History or risk of serotonin syndrome 5. History of acute myocardial infarction within 1 year from day of screening 6. History of seizures within 1 year from day of screening 7. History of benign prostate hypertrophy 8. History of angle-closure glaucoma 9. Subjects with hyperthyroidism or taking thyroid medication 10. History of suicidal ideation as assessed by subject medical history 11. Use of concomitant prescription or non-prescription drugs, dietary supplements, or herbal supplements within 14 days before check-in in Period 1 12. History of difficulty in swallowing. 13. Subjects who donated greater than equal to 500 mL of blood within 56 days prior to check-in in period 1 or greater than equal to 50 mL and less than equal to 499 mL of blood within 30 days prior to check-in in Period 1 14. Subjects who have had a tattoo or body piercing within 30 days prior to check-in in Period 1 15. ECG results indicating QTc greater than 450 msec (male) or greater than 470 msec (female) or QRS greater than 120 msec.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pharmacokinetics of amitriptylineTimepoint: over 24 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| Electrocardiograms (ECGs)Timepoint: Before and after dosing;Incidence, frequency, and intensity of spontaneously reported or observed adverse events (AEs) Timepoint: Till study completion;pharmacokinetics of amitriptylineTimepoint: over 24 hours;pharmacokinetics of nortriptylineTimepoint: over 24 hours;Vital signs (blood pressure, respiratory rate, heart rate, and body temperature) Timepoint: before and after dosing | — |
Countries
India
Contacts
Public ContactDr Mudgal Kothekar MD
Sun Pharma Advanced Research Company Limited
Outcome results
None listed